(Q34507664)

2 August 2017

1 reference

title

Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin (English)

1 reference

2 August 2017

Guay DR

1

1 reference

2 August 2017

publication date

1 December 2001

1 reference

2 August 2017

published in

Clinical Therapeutics

1 reference

2 August 2017

volume

23

1 reference

2 August 2017

issue

12

1 reference

2 August 2017

page(s)

1924-37; discussion 1923

1 reference

Synthesis and oral activity of ME1207, a new orally active cephalosporin

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Synthesis and Oral Activity of Pivaloyloxymethyl 7-((Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido)-3(Z)-(4-methylthiazol-5-yl)vinyl-3-cephem-4-carboxylate(ME1207) and Its Related Compound

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro antibacterial activity of FK041, a new orally active cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro antibacterial activity of ME1207, a new oral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro activity of a new cephalosporin ME-1206 compared with other agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro and in vivo antibacterial activity and pharmacokinetics of SC-002 and its derivative, SC-004: new oral cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae in southwestern Japan and correlation of penicillin-binding protein 2b and 2x mutations in susceptibilities of penicillin G and cefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In-vitro activity of cefditoren against clinical isolates of penicillin-susceptible and resistant strains of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Increasing prevalence of ampicillin- resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980147-8

7 January 2021

10.1016/S0149-2918(01)80147-8

Identifiers

DOI

1 reference

2 August 2017

1 reference